Yuchen Gao

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Particulate Matter

Acute Myocardial Infarction

Signaling Pathway

Top Venues

Signal transduction and targeted therapy

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Yunfei Chen, Yanmei Xu, Ying Chi, Ting Sun, Yuchen Gao, Xueqing Dou, Zhibo Han, Feng Xue, Huiyuan Li, Wei Liu, Xiaofan Liu, Huan Dong, Rongfeng Fu, Mankai Ju, Xinyue Dai, Wentian Wang, Yueshen Ma, Zhen Song, Jundong Gu, Wei Gong, Renchi Yang, Lei Zhang
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial. Signal transduction and targeted therapy 9 (1) (2024)
Yunfei Chen, Yanmei Xu, Ying Chi, Ting Sun, Yuchen Gao, Xueqing Dou, Zhibo Han, Feng Xue, Huiyuan Li, Wei Liu, Xiaofan Liu, Huan Dong, Rongfeng Fu, Mankai Ju, Xinyue Dai, Wentian Wang, Yueshen Ma, Zhen Song, Jundong Gu, Wei Gong, Renchi Yang, Lei Zhang
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial. Signal transduction and targeted therapy 9 (1) (2024)
Yunfei Chen, Yanmei Xu, Ying Chi, Ting Sun, Yuchen Gao, Xueqing Dou, Zhibo Han, Feng Xue, Huiyuan Li, Wei Liu, Xiaofan Liu, Huan Dong, Rongfeng Fu, Mankai Ju, Xinyue Dai, Wentian Wang, Yueshen Ma, Zhen Song, Jundong Gu, Wei Gong, Renchi Yang, Lei Zhang
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial. Signal transduction and targeted therapy 9 (1) (2024)
Yunfei Chen, Yanmei Xu, Ying Chi, Ting Sun, Yuchen Gao, Xueqing Dou, Zhibo Han, Feng Xue, Huiyuan Li, Wei Liu, Xiaofan Liu, Huan Dong, Rongfeng Fu, Mankai Ju, Xinyue Dai, Wentian Wang, Yueshen Ma, Zhen Song, Jundong Gu, Wei Gong, Renchi Yang, Lei Zhang
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial. Signal transduction and targeted therapy 9 (1) (2024)
Yuchen Gao, Ying Chi, Yunfei Chen, Wentian Wang, Huiyuan Li, Wenting Zheng, Caiying Zhu, Jinying An, Yanan Duan, Ting Sun, Xiaofan Liu, Feng Xue, Wei Liu, Rongfeng Fu, Zhibo Han, Yingchi Zhang, Renchi Yang, Tao Cheng, Jun Wei, Lei Zhang, Xiao-Min Zhang
Multi-omics analysis of human mesenchymal stem cells shows cell aging that alters immunomodulatory activity through the downregulation of PD-L1. Nature communications 14 (1) (2023)